The InterVapor system uses the body’s natural healing processes without leaving foreign materials behind to directly target the hyperinflation in the lungs.
In previous clinical studies, InterVapor system has demonstrated clinically meaningful improvements in lung function, exercise capacity and quality of life at six months.
Uptake Medical president and CEO King Nelson said they look forward to working with its distributor partner, Aurora BioScience, to launch InterVapor system in Australia next year.
Alfred Hospital in Melbourne, Australia professor Gregory Snell said InterVapor has continued to demonstrate clinical efficacy and safety and they look forward to offering InterVapor to their patients.
